TD Cowen analyst Joseph Thome raised the firm’s price target on PTC Therapeutics (PTCT) to $63 from $50 and keeps a Hold rating on the shares. The firm said they posted a solid topline beat where nitial Sephience sales of $19.2MM beat the $4MM consensus, and surpassed the higher end of investor expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs
- PTC Therapeutics price target raised to $80 from $68 at JPMorgan
- PTC Therapeutics price target raised to $93 from $73 at Wells Fargo
- PTC Therapeutics price target raised to $68 from $46 at Barclays
- PTC Therapeutics price target raised to $75 from $50 at Citi